GoodRx Holdings (GDRX) AI Stock Analysis

• Market Cap: $909.68M
• Dividend Yield: N/A
• Average Volume (3M): 1.94M
• Price to Earnings (P/E): 30.3
• Beta (1Y): 0.70
• Revenue Growth: 1.30%
• EPS Growth: N/A
• Country: US
• Employees: 738
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.08
• Shares Outstanding: 105,468,834
• 10 Day Avg. Volume: 2,063,890
• 30 Day Avg. Volume: 1,942,391
• PEG Ratio: -0.37
• Price to Book (P/B): 2.48
• Price to Sales (P/S): 2.26
• P/FCF Ratio: 15.80
• Enterprise Value/Market Cap: 1.92
• Enterprise Value/Revenue: 2.18
• Enterprise Value/Gross Profit: 2.39
• Enterprise Value/Ebitda: 9.89
• 1Y Price Target: $4.46
• Price Target Upside: 66.42% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 10
• EPS Forecast (FY): 0.43
• Revenue Forecast (FY): $816.09M

• Rating: 60 Neutral
• Price Target: $3.00 ▲(11.94% Upside)

The score is driven primarily by improving fundamentals—positive TTM profitability, strong margins, and meaningful cash generation—supported by an earnings-call outlook that maintains guidance and shows strong Manufacturer Solutions momentum. These positives are tempered by balance-sheet leverage rising versus equity, declining prescription transaction revenue tied to partner/store disruptions, and a technical setup that remains weaker over longer timeframes. Valuation also appears demanding at a ~33.5 P/E with no dividend yield provided.

Positive Factors

High gross and operating margins

Sustained very high gross margin and solid operating profitability indicate a scalable, software-like economics to GoodRx’s platform. Durable margins permit reinvestment in product, marketing, and partnerships while insulating core earnings from modest revenue variability.

Manufacturer Solutions growth and partnerships

Rapid, high-margin Manufacturer Solutions growth and expanded pharma/retail partnerships (e.g., Novo Nordisk, Amgen, Kroger) diversify revenue away from retail transaction fees. This B2B momentum supports more predictable, contractable revenue streams and deeper commercial moats over time.

Positive cash generation

Meaningful positive operating and free cash flow provides financial flexibility to fund growth, service debt, or pursue strategic initiatives. While FCF has shown some variability, the persistent cash generation is a durable strength for multi-quarter execution and balance-sheet management.

Negative Factors

Rising leverage

Leverage increased materially versus prior year, reducing the equity cushion and raising refinancing and interest-rate risk. Elevated debt limits strategic optionality, increases fixed obligations, and makes the company more vulnerable to slower cash conversion or revenue shocks over the next several quarters.

Transaction-volume and partner concentration risk

Significant reliance on PBM and retail partners for prescription transaction volume creates structural exposure: store closures or PBM program changes can sustainably reduce core transaction revenue. This concentration risk can depress low-margin, high-frequency flows that underpin consumer usage.

Thin net margin and weaker cash conversion

Net profitability remains modest despite gross margin strength, and a notable FCF decline shows cash conversion variability. Thin net margins provide limited shock absorption and constrain reinvestment or accelerated debt reduction if revenue or partner dynamics deteriorate.

GoodRx Holdings Business Overview & Revenue Model

Company Description

GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.

How the Company Makes Money

GoodRx generates revenue through several key streams. The primary source of income comes from the fees it earns when consumers use its platform to obtain discounts on prescription medications. When a user redeems a coupon at a pharmacy, GoodRx receives a transaction fee from the pharmacy or pharmacy benefit manager (PBM). Additionally, GoodRx partners with healthcare providers and telehealth services, earning revenue from telehealth consultations and prescriptions facilitated through its platform. The company also explores advertising opportunities and partnerships with pharmaceutical companies, allowing for additional income through sponsored listings and promotions. These diverse revenue streams contribute to GoodRx's overall earnings, leveraging both consumer engagement and partnerships within the healthcare ecosystem.

GoodRx Holdings Financial Statement Overview

Summary

GoodRx Holdings exhibits strong financial health with significant improvements in profitability and cash flow generation. The company has effectively reduced its leverage, enhancing financial stability. Continued focus on operational efficiency could further improve EBIT margins, supporting sustained growth.

Income Statement

GoodRx Holdings has shown a strong revenue growth rate of 30.8% in the TTM, with a high gross profit margin of 93.68%. The net profit margin has improved significantly to 7.05% from a negative margin in previous years, indicating enhanced profitability. However, the EBIT margin is relatively low at 8.82%, suggesting room for operational efficiency improvements.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.10 in the TTM, indicating a strong reduction in leverage compared to previous years. The return on equity has increased to 8.29%, reflecting better utilization of equity. However, the equity ratio is moderate, suggesting a balanced asset structure.

Cash Flow

GoodRx Holdings has demonstrated a robust free cash flow growth rate of 56.24% in the TTM, with a strong operating cash flow to net income ratio of 1.08. The free cash flow to net income ratio is healthy at 0.77, indicating efficient cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	800.65M	792.32M	750.26M	766.55M	745.42M	550.70M
Gross Profit	728.60M	744.11M	683.34M	701.48M	698.71M	521.11M
EBITDA	176.17M	153.92M	108.82M	65.19M	48.00M	-257.11M
Net Income	31.75M	16.39M	-8.87M	-32.83M	-25.25M	-293.62M
Balance Sheet
Total Assets	1.33B	1.39B	1.59B	1.60B	1.61B	1.49B
Cash, Cash Equivalents and Short-Term Investments	273.53M	448.35M	672.30M	757.16M	941.11M	971.59M
Total Debt	545.13M	543.39M	711.07M	717.02M	702.33M	704.92M
Total Liabilities	724.79M	663.41M	826.84M	789.80M	775.95M	783.23M
Stockholders Equity	600.71M	724.66M	761.96M	814.83M	831.68M	711.36M
Cash Flow
Free Cash Flow	104.92M	113.55M	82.53M	91.57M	144.32M	95.52M
Operating Cash Flow	179.76M	183.89M	138.29M	146.78M	178.78M	131.34M
Investing Cash Flow	-104.83M	-70.35M	-55.77M	-210.50M	-178.73M	-91.62M
Financing Cash Flow	-225.17M	-337.50M	-167.40M	-120.23M	-30.53M	905.82M

GoodRx Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDRX, the sentiment is Negative. The current price of 2.68 is below the 20-day moving average (MA) of 2.77, below the 50-day MA of 2.81, and below the 200-day MA of 3.94, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 40.44 is Neutral, neither overbought nor oversold. The STOCH value of 14.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GDRX.

GoodRx Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GDRX	60 Neutral	$909.68M	30.27	4.90%	―	1.30%	―
PHR	60 Neutral	$988.10M	-163.68	-1.87%	―	14.33%	93.62%
CCLD	58 Neutral	$122.95M	71.25	21.49%	―	2.97%	―
OMDA	56 Neutral	$933.48M	-33.85	―	―	50.51%	50.92%
AMWL	55 Neutral	$77.11M	-0.64	-38.35%	―	4.33%	50.50%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TDOC	47 Neutral	$1.11B	-4.74	-15.42%	―	-2.37%	77.85%

GoodRx Holdings Corporate Events

GoodRx Approves Retention Bonuses for CEO and CFO

On December 9, 2025, GoodRx Holdings‘ Board of Directors approved retention bonus agreements for CEO Wendy Barnes and CFO Chris McGinnis, offering them cash bonuses of $2 million and $1 million, respectively. These bonuses are contingent upon their continued employment, with repayment conditions if they leave the company under certain circumstances before the end of 2027. The agreements exclude them from participating in the company’s 2025 executive bonus plan or other cash incentive programs for that year.

The most recent analyst rating on (GDRX) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on GoodRx Holdings stock, see the GDRX Stock Forecast page.

GoodRx Holdings Co-Chairman Trevor Bezdek Steps Down

On October 31, 2025, GoodRx Holdings announced that Trevor Bezdek, Co-Chairman of the Board, will end his employment and executive officer role with the company upon his contract expiration on November 1, 2025. Despite stepping down from his executive position, Bezdek will continue as a non-employee Co-Chairman of the Board, receiving standard compensation and stock awards under the company’s Non-Employee Director Compensation Program.

The most recent analyst rating on (GDRX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on GoodRx Holdings stock, see the GDRX Stock Forecast page.